Table 28.
One-, Two-, Five- and Ten-Year Relative Survival Ratesa,b for Selected Non-Malignant Brain and Other Central Nervous System Tumors by NCI Age Groups, SEER 18 Registries, 2004-2013c
| Age Group (years) | 1-Year | 2-Year | 5-Year | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Histology | N d | % | 95% CI | % | 95% CI | % | 95% CI | ||
| Unique astrocytoma variants | Childrene (0-14) | 119 | 97.4 | (91.9-99.2) | 97.4 | (91.9-99.2) | 97.4 | (91.9-99.2) | |
| AYAf (15-39) | 85 | 96.3 | (88.8-98.8) | 96.3 | (88.8-98.8) | 93.3 | (84.0-97.3) | ||
| Adults (40+) | -- | -- | -- | -- | -- | -- | -- | ||
| Ependymal tumors | Childrene (0-14) | 64 | 100.0 | ** | 100.0 | ** | 95.0 | (80.6-98.8) | |
| AYAf (15-39) | 435 | 99.6 | (97.7-99.9) | 99.1 | (97.0-99.7) | 98.3 | (95.3-99.4) | ||
| Adults (40+) | 837 | 96.9 | (95.2-98.1) | 96.7 | (94.6-98.0) | 96.7 | (94.6-98.0) | ||
| Choroid plexus tumors | Childrene (0-14) | 146 | 98.8 | (93.9-99.8) | 98.0 | (93.0-99.4) | 94.8 | (88.3-97.8) | |
| AYAf (15-39) | 118 | 98.3 | (92.7-99.6) | 98.3 | (92.7-99.6) | 97.2 | (90.6-99.2) | ||
| Adults (40+) | 125 | 83.6 | (75.2-89.3) | 81.8 | (72.8-88.0) | 75.0 | (63.6-83.3) | ||
| Neuronal and mixed neuronal-glial tumors | Childrene (0-14) | 579 | 98.9 | (97.6-99.5) | 98.5 | (97.0-99.3) | 97.0 | (94.8-98.3) | |
| AYAf (15-39) | 858 | 98.5 | (97.3-99.1) | 98.0 | (96.6-98.8) | 95.3 | (93.2-96.8) | ||
| Adults (40+) | 472 | 92.9 | (89.9-95.1) | 90.9 | (87.3-93.5) | 85.7 | (80.7-89.4) | ||
| Nerve sheath tumors | Childrene (0-14) | 403 | 100.0 | ** | 100.0 | ** | 99.7 | (95.2-100) | |
| AYAf (15-39) | 2,417 | 99.6 | (99.2-99.8) | 99.3 | (98.7-99.6) | 98.9 | (98.0-99.3) | ||
| Adults (40+) | 12,639 | 99.4 | (99.1-99.6) | 99.3 | (98.9-99.6) | 99.3 | (98.9-99.6) | ||
| Meningioma | Childrene (0-14) | 135 | 97.6 | (92.6-99.2) | 96.6 | (91.1-98.8) | 96.6 | (91.1-98.8) | |
| AYAf (15-39) | 4,322 | 98.7 | (98.3-99.0) | 98.1 | (97.6-98.5) | 96.5 | (95.7-97.2) | ||
| Adults (40+) | 61,501 | 91.8 | (91.5-92.0) | 89.7 | (89.4-90.1) | 85.7 | (85.2-86.1) | ||
| Mesenchymal tumors | Childrene (0-14) | 127 | 99.3 | (91.0-100.0) | 98.1 | (91.0-99.6) | 95.8 | (85.0-98.9) | |
| AYAf (15-39) | 135 | 97.7 | (92.6-99.3) | 97.7 | (92.6-99.3) | 95.0 | (86.5-98.2) | ||
| Adults (40+) | 330 | 95.8 | (92.3-97.7) | 94.8 | (90.6-97.2) | 89.6 | (83.0-93.8) | ||
| Other neoplasms related to the meninges | Childrene (0-14) | -- | -- | -- | -- | -- | -- | -- | |
| AYAf (15-39) | 488 | 97.3 | (95.2-98.4) | 96.9 | (94.7-98.2) | 95.8 | (93.1-97.4) | ||
| Adults (40+) | 992 | 94.0 | (92.1-95.5) | 93.0 | (90.8-94.8) | 89.4 | (86.0-91.9) | ||
| Germ cell tumors, cysts and heterotopias | Childrene (0-14) | 76 | 93.0 | (83.6-97.1) | 93.0 | (83.6-97.1) | 93.0 | (83.6-97.1) | |
| AYAf (15-39) | 77 | 98.6 | (89.4-99.8) | 95.2 | (85.2-98.5) | 95.2 | (85.2-98.5) | ||
| Adults (40+) | 72 | 92.5 | (81.8-97.0) | 92.5 | (81.8-97.0) | 92.5 | (81.8-97.0) | ||
| Tumors of the pituitary | Childrene (0-14) | 360 | 99.7 | (97.7-100) | 99.4 | (97.3-99.9) | 98.3 | (95.1-99.4) | |
| AYAf (15-39) | 9,331 | 99.5 | (99.4-99.7) | 99.4 | (99.2-99.6) | 99.1 | (98.7-99.3) | ||
| Adults (40+) | 21,141 | 97.1 | (96.8-97.4) | 96.4 | (96.0-96.8) | 95.1 | (94.5-95.7) | ||
| Craniopharyngioma | Childrene (0-14) | 385 | 97.2 | (94.9-98.5) | 96.3 | (93.7-97.9) | 92.7 | (88.9-95.3) | |
| AYAf (15-39) | 367 | 95.1 | (92.1-96.9) | 93.1 | (89.7-95.4) | 88.1 | (83.4-91.5) | ||
| Adults (40+) | 813 | 88.3 | (85.7-90.5) | 84.7 | (81.6-87.3) | 77.7 | (73.6-81.3) | ||
| Hemangioma | Childrene (0-14) | 144 | 99.3 | (94.0-99.9) | 99.3 | (94.0-99.9) | 99.3 | (94.0-99.9) | |
| AYAf (15-39) | 649 | 99.8 | (98.3-100.0) | 99.5 | (98.0-99.9) | 99.2 | (97.2-99.8) | ||
| Adults (40+) | 1,462 | 94.9 | (93.4-96.1) | 93.5 | (91.7-95.0) | 91.5 | (88.7-93.7) | ||
| TOTAL: All Non-Malignant Brain and Other Nervous System Tumors g | Children d (0-14) | 2,826 | 98.3 | (97.7-98.7) | 97.8 | (97.2-98.3) | 96.4 | (95.4-97.1) | |
| AYA e (15-39) | 20,053 | 99.0 | (98.9-99.2) | 98.6 | (98.4-98.8) | 97.7 | (97.4-98.0) | ||
| Adults (40+) | 103,164 | 93.1 | (93.0-93.3) | 91.6 | (91.4-91.8) | 88.8 | (88.4-89.1) | ||
**Confidence interval could not be calculated.
aThe cohort analysis of survival rates was utilized for calculating the survival estimates presented in this table. Long-term cohort-based survival estimates reflect the survival experience of individuals diagnosed over the time period, and they may not necessarily reflect the long-term survival outlook of newly diagnosed cases.
bRates are an estimate of the percentage of patients alive at one, two, five, and ten year, respectively. Rates were not presented for categories with 50 or less cases and were suppressed for rates where less than 16 cases were surviving within a category.
cEstimated by CBTRUS using Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2015 Sub (2000-2013) <Katrina/Rita Population Adjustment> - Linked To County Attributes - Total U.S., 1969-2014 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2016, based on the November 2015 submission.
dTotal number of case that occurred within the SEER registries between 2000 and 2013.
eChildren as defined by the National Cancer Institute, see: http://www.cancer.gov/researchandfunding/snapshots/pediatric.
fAdolescents and Young Adults (AYA), as defined by the National Cancer Institute, see: http://www.cancer.gov/researchandfunding/snapshots/adolescent-young-adult.
gIncludes histologies not listed in this table.
Abbreviation: SEER, Survival, Epidemiology and End Results; CI, confidence interval; NOS, not otherwise specified.